Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights

Kiniksa outlined several commercial priorities for 2026, including physician education and marketing initiatives designed to broaden awareness and support earlier use in the disease course. Moat said the company plans to:Management attributed ARCALYST’s growth primarily to expanding adoption of IL-1 pathway inhibition as a second-line treatment immediately after failure of NSAIDs and colchicine. Moat pointed to the publication of the 2025 ACC Concise Clinical Guidance , which he said recommends IL-1 pathway ...